Showing 26,881 - 26,900 results of 28,660 for search 'Classification three', query time: 0.28s Refine Results
  1. 26881
  2. 26882
  3. 26883
  4. 26884
  5. 26885
  6. 26886
  7. 26887
  8. 26888
  9. 26889
  10. 26890
  11. 26891
  12. 26892

    Benchmarking solutions to the T-cell receptor epitope prediction problem: IMMREP22 workshop report by Pieter Meysman, Justin Barton, Barbara Bravi, Liel Cohen-Lavi, Vadim Karnaukhov, Elias Lilleskov, Alessandro Montemurro, Morten Nielsen, Thierry Mora, Paul Pereira, Anna Postovskaya, María Rodríguez Martínez, Jorge Fernandez-de-Cossio-Diaz, Alexandra Vujkovic, Aleksandra M. Walczak, Anna Weber, Rose Yin, Anne Eugster, Virag Sharma

    Published 2023-03-01
    “…This benchmark revealed that the use of paired-chain alpha-beta, as well as CDR1/2 or V/J information, when available, improves classification obtained with CDR3 data, independent of the underlying approach. …”
    Get full text
    Article
  13. 26893
  14. 26894

    Comparison of circulating immune signatures across different consensus molecular subtypes (CMS) and between left- and right-sided lesions in stage II colorectal cancer using single... by Pin Gao, Chuanyong Zhou, Hong Yang, Shunyu Deng, Beihai Jiang, Zaozao Wang, Jiabo Di, Xiangqian Su

    Published 2025-05-01
    “…We then compared the immune cell phenotypes and frequencies based on tumor location and CMS classification in patients with stage II CRC. Wilcoxon test was employed to compare the mean frequencies of cell clusters between different tumor locations. …”
    Get full text
    Article
  15. 26895

    External Validation of the International Staging Collaboration for Cancer of the Prostate (STAR-CAP) Prognostic System in Patients Managed with Active Surveillance by Alejandro Berlin, Matthew Ramotar, Antonio Finelli, Zhihui Liu, Liying Zhang, Laurence Klotz, Andrew Loblaw, Danny Vesprini

    Published 2025-09-01
    “…The estimated 10-yr and 15-yr PCSM incidence rates were 0.4% (95% confidence interval [CI] 0.1–1.0%) and 1.1% (95% CI 0.3–2.9%) at PMH, and 1.35% (95% CI 0.79–2.18%) and 3.15% (95% CI 2.14–4.47%) at OCC, respectively. …”
    Get full text
    Article
  16. 26896

    Incidence of Strabismus in Childhood Glaucoma by Kaersti L. Rickels, BA, Muhammad Z. Chauhan, MD, MS, Linda R. Dagi, MD, Abdulrahman Rageh, MD, Isdin Oke, MD, MPH, Paul H. Phillips, MD, Abdelrahman M. Elhusseiny, MD, MSc

    Published 2025-11-01
    “…Methods: Patients were identified using the International Classification of Diseases Ninth and 10th Revision codes. …”
    Get full text
    Article
  17. 26897
  18. 26898

    Smaller and thinner long bones in children and adolescents with cerebral palsy and other neuromotor impairments by Erin Hodgson, Erin Hodgson, Erin Hodgson, Erin Hodgson, Elizabeth G. Condliffe, Elizabeth G. Condliffe, Elizabeth G. Condliffe, Elizabeth G. Condliffe, Elizabeth G. Condliffe, Leigh Gabel, Leigh Gabel, Leigh Gabel, Leigh Gabel

    Published 2025-06-01
    “…ObjectivesThis study quantified bone and muscle health in children and adolescents with CP and other neuromotor impairments across all five gross motor function classification system (GMFCS) levels.MethodsPeripheral quantitative computed tomography (pQCT) scans of both tibiae were acquired at the 3%, 38%, and 66% of tibia length in 22 children and adolescents (4–17 years old) diagnosed with CP and “CP-like” neurodevelopmental conditions causing motor impairment. …”
    Get full text
    Article
  19. 26899

    Hospital frailty risk score in predicting outcomes after simultaneous colon and liver resection for colorectal cancer liver metastasis in older adults: Evidence from the Nationwide... by Haohao Huang, Weidong Jin, Huiling Sun, Bo Diao, Ping Wang, Jiankun Jia, Dandan Ma, Yi Zhang

    Published 2025-08-01
    “…Frailty was significantly associated with increased risks of in-hospital mortality (adjusted odds ratio [aOR] = 3.65, 95% confidence interval [CI]: 2.52, 5.28), non-routine discharge (aOR = 2.44, 95% CI: 2.08, 2.87), prolonged LOS (aOR = 3.07, 95% CI: 2.60, 3.61), overall complications (aOR = 3.47, 95% CI: 3.03, 3.97), sepsis (aOR = 13.73, 95% CI: 9.76, 19.31), respiratory failure (aOR = 4.99, 95% CI: 3.80, 6.57), acute kidney injury (AKI) (aOR = 6.42, 95% CI: 4.83, 8.52), and acute liver failure (aOR = 2.10, 95% CI: 1.38, 3.21), as well as 32.69 thousand USD higher total hospital costs (95% CI: 28.41, 36.97) than no frailty. …”
    Get full text
    Article
  20. 26900

    Combined modality radiotherapy for high-risk prostate cancer. Analysis of treatment-Related complications by K. S. Makarova, Yu. V. Gumenetskaya, V. A. Biryukov, A. A. Obukhov, I. A. Strikanova, S. O. Dzhabrailova, O. G. Lepilina, N. B. Borysheva, O. B. Karyakin, S. A. Ivanov, A. D. Kaprin

    Published 2019-04-01
    “…Short-term outcomes after combined modality radiotherapy were analyzed in 88 prostate cancer patients treated at clinic of the a.F. tsyb medical Radiological Research center between april 2016 and February 2018. the median follow-up time was 13 months (range, 3–23 months). the mean age of the patients was 64.8 years (range, 49–80 years). an initial psawas in the range of 3.5–114 ng/ml (mean 16.7 ng/ml). all patients were considered high-risk according to the d’amico classification. the patients were divided into two groups according to the sequence of combined modality radiotherapy. in group 1, the patients (n=45) received conformal EBRtto a total dose of 44–46 gy, and 2–3 weeks later, they underwent high–dose rate 192ir- brachytherapy (one single fraction of 15 gy) as a boost to EBRt. in group 2, the patients (n=43) were treated with interstitial brachytherapy followed by EBRtdelivering at total doses of 44–46 gy.Results. …”
    Get full text
    Article